May 26

Health Canada Warns Heart Patients to AVOID ADHD Drugs

Despite the stack of empirical evidence—from clinical trials and MedWatch adverse drug event reports—linking these drugs to serious adverse effects–the FDAcontinues to drag its feet.  Between 1990-2000 the FDA received 186 reports of deaths–that reflects only 1% of adverse events. Yet, the FDA did nothing to warn physicians or parents.

The FDA ignores the recommendations of cardiologgists, ignores its own safety officers’ recommendations, and ignores the rising number of drug-casualties.

What’s more FDA ignores the controversy swirling around the reckless prescribing of drugs that, according to the head of the National Institute of Drub Abuse, are more potent than cocaine.  Psychostimulants are prescribed for so-called ADHD– an exceedingly controversial "disorder"  that, thanks to Eli Lilly’s aggressive advertising campaign direct to consumers, has increased to $3.1 billion.  

Until Eli Lilly launched Strattera (2002), ADHD drugs were prescribed only for children. Since then prescriptions for adults shot up 90%.

Who is benefiting?

 
Contact: Vera Hassner Sharav
212-595-8974
veracare@ahrp.org
 

 http://news.yahoo.com/s/nm/20060526/hl_nm/canada_drugs_dc_3 

Avoid ADHD drugs, Canada tells heart patients

50 minutes ago

OTTAWA (Reuters) – Canada’s health ministry on Friday warned people with high blood pressure, heart disease and a number of other medical ailments not to take drugs used to manage Attention Deficit Hyperactivity Disorder (ADHD).

Health Canada said that in rare cases, people with these conditions who took the drugs could suffer "rare heart-related side effects." In a statement, it warned people not to give up the drugs before consulting their doctor.

Millions take the drugs to treat attention deficit hyperactivity disorder, which causes trouble with focus as well as hyperactivity and impulsiveness.

"All ADHD drugs stimulate the heart and blood vessels … The effects are usually mild or moderate, but in some patients this stimulation may — in rare cases — result in cardiac arrests, strokes or death," said Health Canada.

The drugs should be shunned by those with high blood pressure, heart disease or abnormalities, hardening of the arteries or those with an overactive thyroid gland, it added.

Reviewers at the U.S.
   
Food and Drug Administration (FDA) have been working for months to analyze reports of sudden deaths, heart attacks and strokes as well as psychotic behavior such as hallucinations suffered by those who took the drugs.

In March, a panel of U.S. medical advisors called for new information about heart risks to be added to labeling for ADHD medications but stopped short of recommending tougher measures.

The drugs mentioned by Health Canada include:

* Adderall XR, made by Britain’s Shire Pharmaceuticals Group Plc

* Concerta, made by Johnson & Johnson

* Ritalin and Ritalin SR, made by Novartis AG

* Dexedrine, made by GlaxoSmithKline Plc

* Strattera, made by Eli Lilly and Co.

FAIR USE NOTICE: This may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a ‘fair use’ of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.


Subscribe To Our Newsletter!

Sign up and be the first to find out the latest news and articles about what's going on in the medical field.


You may also like

November 21, 2023

Vera Sharav is joining Christine Anderson as special guest for the Make It Your Business event in

Read More
Vera Sharav Joins Christine Anderson for Make It Your Business – Dec 4, 2023 in New Jersey

November 21, 2023

Vera Sharav is premiering the movie Never Again is Now Global in New York City, December 1.

Read More
Never Again is Now Global – Premiere Screening – Dec 1, 2023 in New York City